Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression.

Much emphasis has been placed on participant's psychological safety within genomic research studies; however, few studies have addressed parental psychological health effects associated with their child's participation in genomic studies, particularly when parents meet the threshold for clinical con...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Genetic Counseling Vol. 31; no. 1; pp. 218 - 230
Autores principales: Schwartz, Talia S., Christensen, Kurt D., Uveges, Melissa K., Waisbren, Susan E., McGuire, Amy L., Pereira, Stacey, Robinson, Jill O., Beggs, Alan H., Green, Robert C., Bachmann, Gloria A., Rabson, Arnold B., Holm, Ingrid A.
Formato: clinical trial research tables/charts Journal Article
Publicado: Wiley-Blackwell Feb2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155059947&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 155059947
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10597700
        41A
      jtl: Journal of Genetic Counseling
      issn: 10597700
      maglogo: N
    pubinfo:
      dt: Feb2022
      vid: 31
      iid: 1
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        155059947
        151572492
        155059947
        155059947
        10.1002/jgc4.1475
        155059947
      ppf: 218
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression.
      aug:
        au:
          Schwartz, Talia S.
          Christensen, Kurt D.
          Uveges, Melissa K.
          Waisbren, Susan E.
          McGuire, Amy L.
          Pereira, Stacey
          Robinson, Jill O.
          Beggs, Alan H.
          Green, Robert C.
          Bachmann, Gloria A.
          Rabson, Arnold B.
          Holm, Ingrid A.
        affil: Division of Genetics and Genomics, Boston Children's Hospital, Boston Massachusetts,, USA
      sug:
        subj:
          Depression Risk Factors
          Parents Psychosocial Factors
          Genome Evaluation
          Sequence Analysis
          Research Subjects In Infancy and Childhood
          Human
          Child
          Mothers
          Fathers
          Mental Health
          Health Screening
          After Care
          Thematic Analysis
          Pediatric Care
          Clinical Trials
          Descriptive Statistics
          Edinburgh Postnatal Depression Scale
          Scales
          Psychological Tests
          Child: 6-12 years
      ab: Much emphasis has been placed on participant's psychological safety within genomic research studies; however, few studies have addressed parental psychological health effects associated with their child's participation in genomic studies, particularly when parents meet the threshold for clinical concern for depression. We aimed to determine if parents' depressive symptoms were associated with their child's participation in a randomized‐controlled trial of newborn exome sequencing. Parents completed the Edinburgh Postnatal Depression Scale (EPDS) at baseline, immediately post‐disclosure, and 3 months post‐disclosure. Mothers and fathers scoring at or above thresholds for clinical concern on the EPDS, 12 and 10, respectively, indicating possible Major Depressive Disorder with Peripartum Onset, were contacted by study staff for mental health screening. Parental concerns identified in follow‐up conversations were coded for themes. Forty‐five parents had EPDS scores above the clinical threshold at baseline, which decreased by an average of 2.9 points immediately post‐disclosure and another 1.1 points 3 months post‐disclosure (both p ≤.014). For 28 parents, EPDS scores were below the threshold for clinical concern at baseline, increased by an average of 4.7 points into the elevated range immediately post‐disclosure, and decreased by 3.8 points at 3 months post‐disclosure (both p <.001). Nine parents scored above thresholds only at 3 months post‐disclosure after increasing an average of 5.7 points from immediately post‐disclosure (p <.001). Of the 82 parents who scored above the threshold at any time point, 43 (52.4%) were reached and 30 (69.7%) of these 43 parents attributed their elevated scores to parenting stress, balancing work and family responsibilities, and/or child health concerns. Only three parents (7.0%) raised concerns about their participation in the trial, particularly their randomization to the control arm. Elevated scores on the EPDS were typically transient and parents attributed their symptomatology to life stressors in the postpartum period rather than participation in a trial of newborn exome sequencing.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N